ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2076

Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus

Zahi Touma1, Sheena Kayaniyil2, Anna Parackal2, Dennisse Bonilla1, Jiandong Su1, Christina Qian3, Sally Miller3, Shelagh Szabo3 and Shelly Chandran2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2AstraZeneca, Mississauga, ON, Canada, 3Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada

Meeting: ACR Convergence 2022

Keywords: Cohort Study, corticosteroids, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the introduction of an SLE-approved biologic more than ten years ago, the potential for change in treatment practices related to CS use may be observed. This study examined the use of CS and the impact of CS use on irreversible organ damage in a longitudinal SLE cohort.

Methods: A retrospective observational study was conducted using data from a large SLE cohort in Canada. Adult patients (meeting ≥4 ACR SLE classification criteria, or 3 criteria and biopsy), without lupus nephritis or central nervous system lupus at entry into the cohort were included in the study. Patients were followed from index (time of entry into cohort) to last available clinic visit, with a minimum of 24 months of follow-up. Demographic and clinical characteristics including disease activity (SLEDAI-2K), treatment data and organ damage (SLICC/ACR Damage Index (SDI)) as the primary outcome stratified by CS use was assessed.

Results: A total of 1,255 patients were included (mean (standard deviation [SD]) follow-up duration of 10.5 (8.6) years, 1,111 (89%) female, and 815 (65%) White). Mean (SD) age at study entry was 35.4 (13.7) years. At index, there were 637 (51%) patients with moderate-to-severe disease activity (SLEDAI-2K ≥ 6) (Table 1). 182 (15%) patients had organ damage at index. Approximately 50% of the cohort were on antimalarials, CS, and immunosuppressants at any point during follow-up. Of those with moderate-to-severe disease activity at their last visit in the cohort, 57% were taking CS ≥ 10mg/day during their last year in the cohort. Biologic (belimumab and rituximab) use was < 3% at any point during the follow-up. Almost all patients (n=1,011, 99%) had long-term ( >6 months) cumulative CS exposure. Organ damage (SDI >0) was higher in patients with higher average CS dose and greater years of CS exposure (Table 2). The proportion of patients with any damage increased with average daily CS dose across multiple organ systems (Table 3).

Conclusion: This study in a large cohort of SLE patients shows that despite current standard of care, many SLE patients are still receiving high CS doses, especially with moderate to severe disease. High CS use was associated with irreversible organ damage. Low use of biologics was largely driven by the lack of options and lack of public access to belimumab in Canada. These findings highlight the continued unmet need in the management of SLE patients, particularly in those with moderate-to-high disease severity. Access to novel CS-sparing treatment options is critical to improve long-term outcomes for patients with SLE.

Supporting image 1

Table 1 Patient demographics and disease characteristics at index and during follow-up

Supporting image 2

Table 2 CS overall and by organ damage (SDI)

Supporting image 3

Table 3 Organ damage over follow-up stratified by average daily CS dose, in those with moderate-to-severe SLE (SLEDAI_2K ≥ 6) at baseline


Disclosures: Z. Touma, None; S. Kayaniyil, AstraZeneca; A. Parackal, AstraZeneca; D. Bonilla, None; J. Su, None; C. Qian, None; S. Miller, None; S. Szabo, None; S. Chandran, AstraZeneca.

To cite this abstract in AMA style:

Touma Z, Kayaniyil S, Parackal A, Bonilla D, Su J, Qian C, Miller S, Szabo S, Chandran S. Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/unfavorable-outcomes-associated-with-current-standard-of-care-in-the-management-of-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unfavorable-outcomes-associated-with-current-standard-of-care-in-the-management-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology